Skip to main content
Clinical Trials/JPRN-UMIN000010227
JPRN-UMIN000010227
Completed
Phase 2

Multicenter phase II trial of neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin for HER2-positive operable breast cancer: KBOG-1204 trial - Neoadjuvant TCbH therapy for HER2-positive breast cancer: KBOG-1204 trial

Kanagawa Breast Oncology Group (KBOG)0 sites40 target enrollmentMarch 12, 2013

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Kanagawa Breast Oncology Group (KBOG)
Enrollment
40
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 12, 2013
End Date
June 30, 2015
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Kanagawa Breast Oncology Group (KBOG)

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) drug allergy 2\) severe complications (malignant hypertension, congestive heart failure, coronary heart disease, myocardial infarction (onset within 6 months), arrhythmia (treated), infectious disease, bleeding tendency, etc) 3\) feber, infection 4\) peripheral neuropathy 5\) pleural effusion, pericardial effusion 6\) active double cancer 7\) inflammatory breast cancer 8\) bilateral breast cancer, male breast cancer 9\) pregnancy 10\) severe edema 11\) interstitial pneumonia, fibrous lung disease 12\) steroid\-using patients 13\) psychosomatic disease 14\) unsuitable patients

Outcomes

Primary Outcomes

Not specified

Similar Trials